$2trillion
Annual losses from antibiotic resistance of world GDP
10million
Annual population losses from antibiotic resistance
MDR
Diseases caused by multidrug-resistant bacterial pathogens
7years
Antibiotics development time until approval
Innovative methods to antibiotic replacement
The mission of Stemtrix Corp. is to bring to the market a group of drugs for the treatment of infectious diseases, which will allow: to avoid the development and block the existing mechanisms of resistance; reduce the virulence and size of pathogen populations
The spread of antibiotic-resistant strains
The widespread and uncontrolled use of antibiotics has given rise to the spread of antibiotic-resistant strains. One of the reasons is the industrial use of antibiotics in the rearing of farm animals, technologically providing for their use to ensure proper productivity.
Why Stemtrix is a revolutionary alternative to antibiotics?
Stemtrix preparations do not kill, but serve as mediators of the transition of their pathogens from an active state to a vegetative one. Stemtrix is a radical reduction in the use of antibacterial drugs and antibiotics. The drugs are intended for the prevention and treatment of intestinal and other inflammatory infections of a bacterial nature.
Component of feeds
The active substances of the drug are natural components of the diets of farm animals and birds used in medicine and food industry
No resistance
The active ingredients of the drug are natural regulators of metabolic processes in the bacterial cell, as a result the bacterial cell has no mechanisms of resistance
Without destruction
The drugs will suppress virulence, pathogenicity of pathogenic bacteria, without resorting to the principle of direct destruction of the bacterium
Immune system
The preparations also include substances that modulate the immune response to the introduction of pathogenic bacteria into the body
Results of production tests
Results of Rezovet®
The obtained results of the study of the use of Rezovet in production conditions give grounds for its use as an effective tool for the prevention and treatment of such bacterial infections as: hemophilosis, colibacillosis, mycoplasmosis, pasteurellosis, pullorosis, necrotic enteritis, salmonellosis and its use in the standard scheme of poultry rearing.
Results of Rezomast®
Rezomast does not contain antibiotics, does not have waiting periods for milk, has a stable and long-lasting therapeutic efficacy, helps to stop inflammatory changes in the breast tissue and reduces the risk of recurrence of the disease. The results of the study of the use of Rezomast in industrial conditions give grounds for its use as an effective tool for the treatment of subclinical and clinical mastitis.